Acadia Pharmaceuticals received FDA approval for DAYBUE STIX, a powder formulation of trofinetide for oral solution for Rett syndrome in patients two years and older. The decision expands treatment options for a rare neurodevelopmental disorder and provides a dye‑ and preservative‑free formulation intended to improve dosing convenience for pediatric and adult patients. Acadia said the new product is expected to match the established efficacy and safety profile of existing trofinetide formulations and could facilitate broader patient access. Commercial rollout and manufacturing scale‑up are next steps.